Verily Announces Plans for IBD Registry in Collaboration with Chrohn’s & Colitis Foundation

Late last month, the Alphabet subsidiary Verily announced it will expand its pilot program with the Chrohn’s & Colitis Foundation to build a data registry of patients with irritable bowel disorder (IBD). The updated registry will include symptoms and patient concerns, and will be used to further research into the underlying mechanisms and etiology of the disease.

According to Andrea Park, “The resulting tech-enabled registry will gather data from patients with Crohn’s disease and ulcerative colitis over time. The project aims to go beyond the clinical data collected in electronic health records by incorporating self-reported information about patients’ everyday symptoms, readings taken by wearable devices and sensors and potentially even geolocation data that Abernethy said could provide information about an individual’s environmental exposure risks.”

To read more, click here.

(Source: Fierce Biotech, October 25^th, 2022)